Atopic dermatitis: ruxolitinib cream shows benefits for pruritus and QoL in phase 2 trial

  • Kim BS & al.
  • J Am Acad Dermatol
  • 11 feb. 2020

  • de Brian Richardson, PhD
  • Clinical Essentials
El acceso al contenido completo es sólo para profesionales sanitarios registrados. El acceso al contenido completo es sólo para profesionales sanitarios registrados.

Takeaway

  • Ruxolitinib cream, a Janus kinase inhibitor, was associated with reduced itch and improved QoL for patients with atopic dermatitis (AD) in a phase 2 randomized controlled trial.

Why this matters

  • AD is associated with significant pruritus and impaired QoL.

Key results

  • Ruxolitinib cream 1.5% twice daily was associated with higher mean improvement rates compared with vehicle:
    • Within 36 hours: 42.5% vs 13.6% (P<.01>
    • At week 8: 68.5% vs 17.6% (P<.0001>
  • Itch reduction was associated with reduced QoL burden (P<.001>
  • Ruxolitinib cream 1.5% twice daily was associated with improved QoL (Skindex-16 overall score) vs vehicle at:
    • Week 2: 63.5% vs 10.5% (P<.001>
    • Week 8: 73.2% vs 19.7% (P<.001>

Study design

  • 307 patients with AD with Investigator’s Global Assessment score of 2/3 and 3%-20% affected body surface area were randomly allocated to ruxolitinib cream (1.5% twice daily, 1.5% once daily, 0.5% once daily, or 0.15% once daily), vehicle twice daily, or triamcinolone cream 0.1% twice daily/vehicle for 8 weeks.
  • Funding: Incyte Corporation.

Limitations

  • Small patient sample size in each group.
  • Short trial duration.
  • Facial lesions not treated.